Clear Filter

Nov 18, 2021

New Literature Review Highlights Economic Benefits Associated with Achieving Rheumatoid Arthritis Remission

NORTH CHICAGO, Ill., Nov. 18, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the publication of results from a new literature review in Advances in Therapy. The literature review reported that achieving clinical remission in rheumatoid arthritis (RA) is likely to be associated with economic benefits, such as reduced direct and indirect disease-related medical costs compared with other disease activity levels.1

Nov 17, 2021

AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis

NORTH CHICAGO, Ill., Nov. 17, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab, 150 mg, subcutaneous injection at week 0, week 4 and every 12 weeks thereafter) alone or in combination with methotrexate (MTX), for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Marking the second indication for SKYRIZI, the Marketing Authorization will be valid in all member states of the European Union, as well as Iceland, Liechtenstein, Norway and Northern Ireland.

Nov 15, 2021

Allergan Aesthetics Celebrates Third Annual BOTOX® Cosmetic (onabotulinumtoxina) Day

IRVINE, Calif., Nov. 15, 2021 /PRNewswire/ -- Let the countdown begin.

Nov 10, 2021

AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025

NORTH CHICAGO, Ill. and CHICAGO, Nov. 10, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) and the University of Chicago and have extended their collaboration agreement through 2025 to support preclinical oncology research.

Nov 10, 2021

AbbVie to Present at the Wolfe Research Healthcare Conference

NORTH CHICAGO, Ill., Nov. 10, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Wolfe Research Healthcare Conference on Wednesday, November 17, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present at 8:30 a.m. Central time.

Nov 09, 2021

AbbVie Presents New Efficacy Data on Upadacitinib (RINVOQ®) in People with Active Psoriatic Arthritis and Axial Involvement at ACR Convergence 2021

NORTH CHICAGO, Ill., Nov. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from new post-hoc analyses from the Phase 3 SELECT-PsA 1 and SELECT-PsA 2 trials assessing the efficacy of upadacitinib (RINVOQ®) on axial symptoms in adult patients with active psoriatic arthritis (PsA) and axial involvement. The analysis showed that patients with active PsA demonstrated numerically greater clinical responses related to their axial involvement with upadacitinib (15 mg, once daily) compared to placebo at week 24 across both studies and consistently numerically higher responses compared to HUMIRA® (adalimumab) at week 24 in SELECT-PsA 1.1

Nov 09, 2021

AbbVie to Present New Long-term Analysis Evaluating the Sustainability of Response to RINVOQ® (Upadacitinib) Among Patients with Rheumatoid Arthritis

NORTH CHICAGO, Ill., Nov. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new results from a post-hoc analysis of the Phase 3 SELECT-BEYOND clinical trial evaluating RINVOQ® (upadacitinib; 15 mg, once daily) in patients with moderate to severe rheumatoid arthritis (RA) on stable background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) with prior inadequate response or intolerance to at least one biologic DMARD.

Nov 08, 2021

Allergan, an AbbVie Company, to Present New Data from its Leading Eye Care Portfolio at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting

NORTH CHICAGO, Ill., Nov. 8, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new pooled post-hoc analyses and patient-reported outcomes (PROs) of VUITYTM (pilocarpine HCl ophthalmic solution) 1.25%, newly approved by the FDA as the first and only eye drop to treat presbyopia; additional analyses on DURYSTA® (bimatoprost intracameral implant); and three real-world data studies on the glaucoma patient journey at the AAO (American Academy of Ophthalmology) 2021 Annual Meeting, November 12-15.

Nov 05, 2021

AbbVie Presents Integrated Efficacy and Safety Data From Two Phase 3 Trials on Risankizumab (SKYRIZI®) in Psoriatic Arthritis at ACR Convergence 2021

NORTH CHICAGO, Ill., Nov. 5, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluating the efficacy and safety of risankizumab (SKYRIZI®) in adult patients with active psoriatic arthritis (PsA). The data showed that 24-weeks of treatment with risankizumab resulted in greater improvements in PsA signs and symptoms compared with placebo with no new safety signals.1 These results will be featured in an American College of Rheumatology (ACR) Convergence 2021 plenary session on Saturday, Nov. 6, from 9:45-10 a.m. CT (Abstract #0453).

Nov 04, 2021

AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting

NORTH CHICAGO, Ill., Nov. 4, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of Hematology (ASH) Annual Meeting (December 11-14) in Atlanta, Georgia.